Twin Focus Capital Partners’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-440
Closed -$298K 184
2025
Q4
$298K Hold
440
0.03% 160
2025
Q3
$281K Hold
440
0.04% 156
2025
Q2
$236K Buy
+440
New +$210K 0.03% 151
2024
Q4
Sell
-440
Closed -$222K 149
2024
Q3
$222K Hold
440
0.04% 138
2024
Q2
$214K Hold
440
0.03% 132
2024
Q1
$238K Hold
440
0.05% 129
2023
Q4
$244K Buy
+440
New +$207K 0.05% 135
2023
Q3
Sell
-862
Closed -$433K 194
2023
Q2
$433K Buy
862
+12
+1% +$5.75K 0.09% 122
2023
Q1
$425K Hold
850
0.08% 121
2022
Q4
$347K Sell
850
-7
-0.8% -$2.72K 0.07% 135
2022
Q3
$279K Buy
857
+4
+0.5% +$1.47K 0.07% 155
2022
Q2
$299K Sell
853
-3
-0.4% -$1.22K 0.07% 149
2022
Q1
$468K Buy
856
+5
+0.6% +$2.63K 0.09% 116
2021
Q4
$560K Buy
851
+400
+89% +$251K 0.11% 101
2021
Q3
$280K Buy
451
+1
+0.2% +$672 0.07% 143
2021
Q2
$284K Buy
450
+10
+2% +$5.52K 0.07% 144
2021
Q1
$215K Hold
440
0.06% 141
2020
Q4
$220K Buy
+440
New +$197K 0.07% 146

Other funds holding IDXX

Twin Focus Capital Partners's IDXX Position: Q1 2026 in Review

Twin Focus Capital Partners sold out of Idexx Laboratories (IDXX) in Q1 2026, closing a stake of 440 shares — an estimated $298K sold.

Twin Focus Capital Partners first reported a position in IDXX in Q4 2020 and held it in 18 quarters. The position peaked at $560K in Q4 2021. 1,316 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

  • Twin Focus Capital Partners reported no remaining Idexx Laboratories position as of Q1 2026 after selling out during the quarter.
  • Twin Focus Capital Partners sold 440 Idexx Laboratories shares in Q1 2026, an estimated $298K.
  • Twin Focus Capital Partners first reported a position in Idexx Laboratories in Q4 2020 and held it in 18 quarters.
  • Twin Focus Capital Partners's Idexx Laboratories position peaked at $560K in Q4 2021.
  • 1,316 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Twin Focus Capital Partners's 13F filing for Q1 2026, filed 14 May 2026.